Imugene share price (ASX:IMU) pops 5% in cancer trial update

Why is this cancer therapy company impressing investors today?
The post Imugene share price (ASX:IMU) pops 5% in cancer trial update appeared first on The Motley Fool Australia. –

The Imugene Limited (ASX: IMU) share price is up today on the back of a positive cancer treatment update.

Shares in the biopharma company are currently trading at 50 cents, up 5.26%.

Let’s take a look at what’s going on at Imugene.

What did the company announce?

The Imugene share price is climbing today after the company announced an update regarding a phase 1 clinical trial.

Imugene is developing therapies that aim to use the body’s immune system to treat cancer tumours.

Today, the company announced a second patient with triple-negative breast cancer (TNBC) has been given a dose of CHECKvacc.

CHECKvacc is an oncolytic virotherapy candidate currently in phase 1 clinical trial at the City of Hope cancer research centre in Los Angeles, USA. TNBC is an aggressive form of the disease with a survival rate of just 12 months.

The trial aims to evaluate the safety and efficacy of the administration of CHECKvacc in patients with metastatic TNBC.

The company says the current trial design will involve a dose escalation. It is also planning to expand the trial to 12 patients. The first patient treated with the cancer therapy has had no safety issues to date.

Comment from management

Speaking on the update that’s likely fuelling the Imugene share price today, managing director and CEO Leslie Chong said:

We hope that in time, CHECKvacc provides an improved outcome for the many women who are diagnosed every year with triple-negative breast cancer.

We look forward to seeing the results of this trial and bringing continued updates to the medical community and our stakeholders moving forward.

Imugene share price snap shot

In the past 12 months, the Imugene share price has soared by 298%. It has also risen 398% this year to date.

For perspective, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned 9% in the past year.

The share price low this year is 9 cents, while the yearly high is 63 cents.

The post Imugene share price (ASX:IMU) pops 5% in cancer trial update appeared first on The Motley Fool Australia.

Should you invest $1,000 in Imugene right now?

Before you consider Imugene, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Imugene wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why is the Imugene (ASX:IMU) share price falling today?

The Imugene (ASX:IMU) share price has rocketed 80% since August. Here’s why

Here are the top 10 ASX shares today

Why Calix, Imugene, Legacy Iron Ore, and Lovisa shares are charging higher

Imugene (ASX:IMU) share price leaps 9% on Pfizer, Merck deal

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!